Zobrazit v EDS

Longitudinal experiences of Canadians receiving compassionate access to psilocybin-assisted psychotherapy

Uloženo v:
Podrobná bibliografie
Název: Longitudinal experiences of Canadians receiving compassionate access to psilocybin-assisted psychotherapy
Autoři: de la Salle, Sara, Kettner, Hannes, Thibault Lévesque, Julien, Garel, Nicolas, Dames, Shannon, Patchett-Marble, Ryan, Rej, Soham, Gloeckler, Sara, Erritzoe, David, Carhart-Harris, Robin, Greenway, Kyle
Zdroj: Sci Rep
Scientific Reports, Vol 14, Iss 1, Pp 1-15 (2024)
de la Salle, S, Kettner, H, Thibault Lévesque, J, Garel, N, Dames, S, Patchett-Marble, R, Rej, S, Gloeckler, S, Erritzoe, D, Carhart-Harris, R & Greenway, K T 2024, 'Longitudinal experiences of Canadians receiving compassionate access to psilocybin-assisted psychotherapy', Scientific Reports, vol. 14, no. 1, 16524. https://doi.org/10.1038/s41598-024-66817-0
Scientific Reports, vol 14, iss 1
Informace o vydavateli: Springer Science and Business Media LLC, 2024.
Rok vydání: 2024
Témata: Adult, Male, Compassionate Use Trials, Canada, Psychotherapy - methods, Science, Palliative treatment, Anxiety, Article, Psychedelics, Humans, Hallucinogens - therapeutic use, name=SDG 3 - Good Health and Well-being, Longitudinal Studies, Prospective Studies, Aged, North American People, Depression - drug therapy, Depression, Distress, Anxiety - drug therapy, Middle Aged, 16. Peace & justice, Psilocybin-assisted psychotherapy, Psilocybin, 3. Good health, Psychotherapy, Psilocybin - therapeutic use, Palliative care, Hallucinogens, Quality of Life, Medicine, Female
Popis: Recent clinical trials have found that the serotonergic psychedelic psilocybin effectively alleviates anxiodepressive symptoms in patients with life-threatening illnesses when given in a supportive environment. These outcomes prompted Canada to establish legal pathways for therapeutic access to psilocybin, coupled with psychological support. Despite over one-hundred Canadians receiving compassionate access since 2020, there has been little examination of these ‘real-world’ patients. We conducted a prospective longitudinal survey which focused on Canadians who were granted Section 56 exemptions for legal psilocybin-assisted psychotherapy. Surveys assessing various symptom dimensions were conducted at baseline, two weeks following the session (endpoint), and optionally one day post-session. Participant characteristics were examined using descriptive statistics, and paired sample t-tests were used to quantify changes from baseline to the two-week post-treatment endpoint. Eight participants with Section 56 exemptions (four females, Mage = 52.3 years), all with cancer diagnoses, fully completed baseline and endpoint surveys. Significant improvements in anxiety and depression symptoms, pain, fear of COVID-19, quality of life, and spiritual well-being were observed. Attitudes towards death, medical assistance in dying, and desire for hastened death remained unchanged. While most participants found the psilocybin sessions highly meaningful, if challenging, one reported a substantial decrease in well-being due to the experience. These preliminary data are amongst the first to suggest that psilocybin-assisted psychotherapy can produce psychiatric benefits in real-world patients akin to those observed in clinical trials. Limited enrollment and individual reports of negative experiences indicate the need for formal real-world evaluation programs to surveil the ongoing expansion of legal access to psychedelics.
Druh dokumentu: Article
Other literature type
Popis souboru: application/pdf
Jazyk: English
ISSN: 2045-2322
DOI: 10.1038/s41598-024-66817-0
DOI: 10.25316/ir-19798
Přístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/39019922
https://doaj.org/article/bee797d982a14c5db200e188381efc80
https://pure.qub.ac.uk/en/publications/ddae1d7f-2441-415a-9130-4e2d372310ef
https://escholarship.org/content/qt3v68v0sf/qt3v68v0sf.pdf
https://escholarship.org/uc/item/3v68v0sf
Rights: CC BY
Přístupové číslo: edsair.doi.dedup.....b04dbe24dced42be8c1f9e29fc1c2af2
Databáze: OpenAIRE
Popis
Abstrakt:Recent clinical trials have found that the serotonergic psychedelic psilocybin effectively alleviates anxiodepressive symptoms in patients with life-threatening illnesses when given in a supportive environment. These outcomes prompted Canada to establish legal pathways for therapeutic access to psilocybin, coupled with psychological support. Despite over one-hundred Canadians receiving compassionate access since 2020, there has been little examination of these ‘real-world’ patients. We conducted a prospective longitudinal survey which focused on Canadians who were granted Section 56 exemptions for legal psilocybin-assisted psychotherapy. Surveys assessing various symptom dimensions were conducted at baseline, two weeks following the session (endpoint), and optionally one day post-session. Participant characteristics were examined using descriptive statistics, and paired sample t-tests were used to quantify changes from baseline to the two-week post-treatment endpoint. Eight participants with Section 56 exemptions (four females, Mage = 52.3 years), all with cancer diagnoses, fully completed baseline and endpoint surveys. Significant improvements in anxiety and depression symptoms, pain, fear of COVID-19, quality of life, and spiritual well-being were observed. Attitudes towards death, medical assistance in dying, and desire for hastened death remained unchanged. While most participants found the psilocybin sessions highly meaningful, if challenging, one reported a substantial decrease in well-being due to the experience. These preliminary data are amongst the first to suggest that psilocybin-assisted psychotherapy can produce psychiatric benefits in real-world patients akin to those observed in clinical trials. Limited enrollment and individual reports of negative experiences indicate the need for formal real-world evaluation programs to surveil the ongoing expansion of legal access to psychedelics.
ISSN:20452322
DOI:10.1038/s41598-024-66817-0